Form 4: Immuneering Corp: CEO Zeskind Acquires Shares

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has acquired 2,400 shares of Class A Common Stock.

Summary

• Benjamin J. Zeskind, President and CEO of Immuneering Corp, acquired 2,400 shares of Class A Common Stock on June 23, 2026.
• The weighted average purchase price for these shares was $4.5617, with individual transactions ranging from $4.55 to $4.59.
• Following this transaction, Zeskind beneficially owns 2,315,252 shares directly and 894,927 shares indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider transaction without providing new financial or strategic information.

Positives

• Insider buying by the CEO can signal confidence in the company's future prospects.
• The CEO's direct acquisition of shares demonstrates personal investment in the company's success.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, such as this one from Immuneering Corp, are standard disclosures for insider transactions. These filings are crucial for investors to understand the actions of company executives and directors, which can sometimes provide insights into their perception of the company's value and future performance.

Related Party Transactions

• 894,927 shares are held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz (Dr. Zeskind's spouse) serves as sole trustee.

Stakeholder Impact

• Shareholders: The acquisition by the CEO may be interpreted as a positive signal of confidence in the company's stock.
• Management: Reinforces the alignment of executive interests with shareholder value.

Key Dates

Keywords

Insider Trading, Form 4, Beneficial Ownership, Class A Common Stock, Immuneering Corp, IMRX, CEO, Director